Editorial
Thiazolidinediones for Initial Treatment of Type 2 Diabetes?
N Engl J Med 2006; 355:2477-2480December 7, 2006
- Article
The twin epidemics of obesity and type 2 diabetes mellitus have spawned a public health crisis. In the United States, an estimated 1.5 million new cases of diabetes occur every year,1 and the projected microvascular and cardiovascular complications2 — already the greatest cause of blindness, kidney failure, and amputations in the Western world, and a substantial contributing factor in heart disease — are likely to become the major cause of preventable disease and premature death in this millennium.
The gravity of this epidemic is reflected by evidence-based efforts to stem it.3,4 Moreover, in the United States, approval of five new classes of antidiabetes drugs in the past decade — three in the past year — has been stimulated by the need to keep glycemia in the near-normal range to prevent and delay the long-term complications of diabetes.5,6 The underlying insulin resistance and impaired insulin secretion in patients with type 2 diabetes worsen over time, necessitating the use of increasingly powerful drugs, often in combination, to control glycemic levels.
The increasing number of available medications has left clinicians unsure of which to use first or how to change or combine medications when the metabolic disorder worsens over time. Consensus recommendations for the treatment of type 2 diabetes have recently been published.7 These guidelines emphasize the long-term maintenance of glycemic control, as estimated by levels of glycated hemoglobin, as close to the nondiabetic range as is safely possible. They also emphasize the initiation of treatment with metformin in patients who have newly diagnosed disease (concurrent with lifestyle interventions) and the changing of medications no less frequently than every 3 months if glycated hemoglobin levels are 7% or more (Figure 1Figure 1
Metabolic Management of Type 2 Diabetes.). The algorithm provided in the guidelines includes early, aggressive use of insulin, the most powerful antidiabetes drug, when metabolic goals are not achieved. Of note, thiazolidinediones, sulfonylureas, and insulin were included as possible second-step medications to be combined with metformin and lifestyle interventions if metabolic goals are not achieved or maintained.Thiazolidinediones, which are agonists of the peroxisome-proliferator–activated receptor γ (PPARγ), are one of the new classes of antidiabetes drugs. Early studies suggested that thiazolidinediones were no more effective in lowering glycemia than were older oral medications.8 The results of such studies, together with the side effects of the thiazolidinediones (which include weight gain, fluid retention, and the risk of congestive heart failure), contributed to the decision not to include them in the first-line treatment of diabetes.7 In addition, the cost of brand-name thiazolidinediones is higher than that of generic metformin.
This issue of the Journal includes a report on the multicenter study by Kahn et al.,9 called A Diabetes Outcome Progression Trial (ADOPT), which was sponsored and analyzed by GlaxoSmithKline, the manufacturer of rosiglitazone. The study was designed to test the efficacy of rosiglitazone as first-line monotherapy in patients with recently diagnosed type 2 diabetes. Rosiglitazone was tested against two much older and mechanistically different drugs — glyburide, a long-duration sulfonylurea with a relatively high risk of hypoglycemia, as compared with other sulfonylureas,10 and the biguanide metformin. The choice of time to failure based on a confirmed fasting glucose level of more than 180 mg per deciliter as the primary outcome, rather than one based on glycated hemoglobin levels, seems anachronistic. Glycated hemoglobin is the measure of glycemia that correlates best with the risk of complications and has been used as the metabolic target for therapy for more than a decade, as cited in the design protocol for ADOPT.11 Nevertheless, as compared with metformin and glyburide, rosiglitazone extended the period before treatment failure occurred. At 5 years, when only 20% of the original cohort was being followed, the reported cumulative incidence of treatment failure was 15% in the rosiglitazone group, 21% in the metformin group, and 34% in the glyburide group. The reductions in relative risk among patients receiving rosiglitazone, as compared with metformin (32%) and glyburide (63%), were highly significant.
Despite the reduction in time to failure, according to the primary outcome, the glycated hemoglobin results suggest a clinically less impressive effect. The mean glycated hemoglobin level at 4 years was 0.13 less in the rosiglitazone group than in the metformin group and 0.42 less than in the glyburide group. Similarly, the fraction of the study cohort that was still receiving its assigned treatment and had a glycated hemoglobin level of less than 7% was only 4% higher in the rosiglitazone group than in the metformin group (40% vs. 36%) and 14% higher than in the glyburide group. Although these differences are statistically significant, the relatively small difference in glycated hemoglobin levels achieved over 4 years in the rosiglitazone group as compared with the metformin group is of questionable clinical significance. The benefits of rosiglitazone over glyburide, which is often not recommended for older patients because of its increased risk of hypoglycemia, are more convincing.
The durability of glycemic control in the rosiglitazone group was robust in comparison with that in the glyburide group; however, it was modest in comparison with the durability in the metformin group. Such findings must be tempered by the surprisingly high proportion of patients who withdrew from the study; only about 60% of the cohort completed the study. The loss of so many patients, which required an expansion in the number of patients evaluated and the duration of follow-up, weakens the results, since the outcomes in the entire randomized population cannot be ascertained. The high rate of withdrawal, which was multifactorial and not explained solely on the basis of side effects of the medications, may have been related to the small number of patients who were followed at many of the almost 500 clinical sites.
The choice among antidiabetes medications with similar glycemic-lowering effectiveness is often based on side effects and “value-added” characteristics. ADOPT brings some of the extraglycemic effects of the medications into focus. Weight gain at year 4 was significantly higher with rosiglitazone (2.5 kg) than with glyburide and was much higher (6.9 kg) than with metformin. Some of the weight gain with rosiglitazone was probably a result of fluid retention, even though patients with any degree of heart failure were excluded from participation. The rosiglitazone group had increased use of loop diuretics and statins. Side effects of glyburide, such as weight gain and hypoglycemia, and the gastrointestinal side effects of metformin were also documented.
The hope that thiazolidinediones may affect the underlying pathophysiology of type 2 diabetes by protecting β-cell function and may alter the course of the disease is only weakly supported by ADOPT. The initial improvement in insulin secretion at 1 year was not sustained, and the difference in insulin secretion between rosiglitazone and metformin over time, albeit significant, was small. Improved insulin sensitivity appears to be the most durable effect of rosiglitazone. Finally, a decreased risk of cardiovascular events purportedly shown in another thiazolidinedione study, the controversial Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROACTIVE),12 was not supported by the ADOPT study. In the latter trial, glyburide was associated with fewer serious cardiovascular events.
The authors conclude that the “relative costs of these medications, their profiles of adverse events, and their potential risks and benefits” should be considered in choosing among them. Given the modest glycemic benefit of rosiglitazone (with the risk of fluid retention and weight gain) and higher cost (including the need for more statins and diuretics), metformin remains the logical choice when initiating pharmacotherapy for type 2 diabetes.
Dr. Nathan reports receiving grant support from Novo Nordisk and Sanofi-Aventis for investigator-initiated studies and financial support from GlaxoSmithKline for an educational program. No other potential conflict of interest relevant to this article was reported.
This article was published at www.nejm.org on December 4, 2006.
Source Information
From the Diabetes Center and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.
- References
References
1
Centers for Disease Control and Prevention. National Diabetes Surveillance System. (Accessed November 14, 2006, at http://www.cdc.gov/diabetes/statistics.)
2
Nathan DM . Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-1685
Full Text | Web of Science | Medline3
Diabetes Prevention Program Research Group
Full Text | Web of Science | Medline4
DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
CrossRef | Web of Science | Medline5
The Diabetes Control and Complications Trial Research Group
Full Text | Web of Science | Medline6
UK Prospective Diabetes Study (UKPDS) Group
CrossRef | Web of Science | Medline7
Nathan DM ,Buse JB ,Davidson MB , et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-1721
CrossRef | Web of Science | Medline8
Inzucchi SE . Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-372
CrossRef | Web of Science | Medline9
Kahn SE ,Haffner SM ,Heise MA , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
Full Text | Web of Science | Medline10
Holstein A ,Plaschke A ,Egberts E-H . Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-473
CrossRef | Web of Science | Medline11
Viberti G ,Kahn SE ,Greene DA , et al. A Diabetes Outcome Progression Trial (ADOPT): an internationl multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-1743
CrossRef | Web of Science | Medline12
Dormandy JA ,Charbonnel B ,Eckland DJA , et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
CrossRef | Web of Science | Medline
- Citing Articles (29)
Citing Articles
1
Zafar H Israili. (2011) Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics 18:2, 117-152
CrossRef2
D. R. Matthews, S. Dejager, B. Ahren, V. Fonseca, E. Ferrannini, A. Couturier, J. E. Foley, B. Zinman. (2010) Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes, Obesity and Metabolism 12:9, 780-789
CrossRef3
Joseph A. Aloi, Anthony L. McCall. 2010. How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. , 494-513.
CrossRef4
Valmore Bermúdez, Freddy Finol, Nailyn Parra, Maria Parra, Adriana Pérez, Lianny Peñaranda, Daviel Vílchez, Joselyn Rojas, Nailet Arráiz, Manuel Velasco. (2010) PPAR-γ Agonists and Their Role in Type 2 Diabetes Mellitus Management. American Journal of Therapeutics 17:3, 274-283
CrossRef5
J. Wang, J. Siegert, U. Maywald, B. Brecht, J. Schröder, U. Heinrich-Gräfe, W. Kirch. (2010) Antidiabetikaverordnungen (2003–2006). Prävention und Gesundheitsförderung 5:2, 159-168
CrossRef6
J. L. Sievenpiper, C. W. C. Kendall, A. Esfahani, J. M. W. Wong, A. J. Carleton, H. Y. Jiang, R. P. Bazinet, E. Vidgen, D. J. A. Jenkins. (2009) Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. Diabetologia 52:8, 1479-1495
CrossRef7
Michael A. Nauck. (2009) Unraveling the Science of Incretin Biology. European Journal of Internal Medicine 20, S303-S308
CrossRef8
Eduardo Carracedo-Martínez, Agustin Pia-Morandeira. (2009) Metformina también como primera elección en pacientes con peso normal. ¿Se ha incrementado su uso?. Atención Primaria 41:6, 324-328
CrossRef9
Andrew Krentz. (2009) Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Diabetes/Metabolism Research and Reviews 25:2, 112-126
CrossRef10
Jochen Wöhrle, Nikolaus Marx, Wolfgang Koenig, Vinzenz Hombach, Hans A. Kestler, Martin Höher, Thorsten Nusser. (2008) Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. Clinical Research in Cardiology 97:10, 726-733
CrossRef11
Kevin B Moore, Christopher D Saudek. (2008) Therapeutic Potential of Dipeptidyl Peptidase-IV Inhibitors in Patients With Diabetes Mellitus. American Journal of Therapeutics 15:5, 484-491
CrossRef12
Pantelis A. Sarafidis. (2008) Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundamental & Clinical Pharmacology 22:3, 247-264
CrossRef13
L. Monnier, C. Colette, D.R. Owens. (2008) Type 2 diabetes: A well-characterised but suboptimally controlled disease. Can we bridge the divide?. Diabetes & Metabolism 34:3, 207-216
CrossRef14
Andrew J. Krentz. (2008) Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. Current Medical Research and Opinion 24:2, 401-417
CrossRef15
S. M. Beard, L. McCrink, T. K. Le, A. Garcia-Cebrian, B. Monz, R. A. Malik. (2008) Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK*. Current Medical Research and Opinion 24:2, 385-399
CrossRef16
Toshihide Kawai, Osamu Funae, Akira Shimada, Mitsuhisa Tabata, Takumi Hirata, Yoshihito Atsumi, Hiroshi Itoh. (2008) Effects of Pretreatment with Low-dose Metformin on Metabolic Parameters and Weight Gain by Pioglitazone in Japanese Patients with Type 2 Diabetes. Internal Medicine 47:13, 1181-1188
CrossRef17
Jonathan J. Shuster, Lynn S. Jones, Daniel A. Salmon. (2007) Fixedvs random effects meta-analysis in rare event studies: The Rosiglitazone link with myocardial infarction and cardiac death. Statistics in Medicine 26:24, 4375-4385
CrossRef18
Janaka Karalliedde, Robin E Buckingham. (2007) Choice of monotherapy in newly diagnosed Type 2 diabetic patients: clinical perspective of ADOPT. Therapy 4:5, 535-540
CrossRef19
E. Bonora. (2007) Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. International Journal of Clinical Practice 61, 19-28
CrossRef20
Shirwan A. Mirza. (2007) Type 2 Diabetes: The End of Clinical Inertia. Southern Medical Journal 100:8, 765-766
CrossRef21
Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christine Clar, Susanne H Ebrahim, Bernd Richter. 2007. Rosiglitazone for type 2 diabetes mellitus. .
CrossRef22
Johanna Kuusisto, Laura Andrulionyte, Markku Laakso. (2007) Atherosclerosis and cardiovascular risk reduction with PPAR agonists. Current Atherosclerosis Reports 9:4, 274-280
CrossRef23
Isabel Howat, Stephen J. Cleland. (2007) Should we now ADOPT glitazones earlier in treatment of type 2 diabetes?. International Journal of Clinical Practice 61:7, 1071-1073
CrossRef24
Anthony Barnett, Josie Allsworth, Kevin Jameson, Rachel Mann. (2007) A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Current Medical Research and Opinion 23:7, 1493-1507
CrossRef25
Psaty, Bruce M., Furberg, Curt D., . (2007) Rosiglitazone and Cardiovascular Risk. New England Journal of Medicine 356:24, 2522-2524
Full Text26
Ozlem Tarcin, Mandeep Bajaj, Sema Akalin. (2007) Insulin Resistance, Adipocyte Biology, and Thiazolidinediones: A Review. Metabolic Syndrome and Related Disorders 5:2, 103-115
CrossRef27
(2007) New Treatments for Diabetes. New England Journal of Medicine 356:21, 2219-2223
Full Text28
J.L. Leahy. (2007) Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. Yearbook of Endocrinology 2007, 60-63
CrossRef29
J.L. Leahy. (2007) Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. Yearbook of Medicine 2007, 471-474
CrossRef
